Rosiglitazone Adjunct to Sertraline for Major Depressive Disorder: A Randomized, Double‐Blind, Placebo‐Controlled Trial
Depression and Anxiety · 2026-01 · 2026 (1)
DOI: 10.1155/da/5812795 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Depression and Anxiety, online erschienen am 17.07.2026. Verfasst von Ahmad Shamabadi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran, tums.ac.ir. Hauptthemen laut MEDLINE: Major Depressive Disorder, Sertraline, Thiazolidinediones, Antidepressive Agents. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Insufficient responses to available treatments for major depressive disorder (MDD) underscores the necessity for innovative therapeutic strategies. This study investigated the efficacy of adjunctive rosiglitazone, an antidiabetic agent with neuroprotective and anti‐inflammatory effects, for MDD. In this 6‐week randomized, parallel‐group, double‐blind, placebo‐controlled clinical trial, patients with MDD were assigned to receive sertraline along with either rosiglitazone 2 mg or a matched placebo q12 h. Participants were evaluated using the Hamilton depression rating scale (HDRS) at baseline and weeks 2, 4, and 6. The difference in its score changes to the endpoint was the primary outcome. Side effects were documented as well. The participants had comparable baseline characteristics. A significant time –treatment interaction effect was observed for HDRS scores ( = 0.052), with the rosiglitazone group experiencing significantly greater reductions at weeks 2 (Cohen’s d = 0.507), 4 (Cohen’s d = 0.556), and 6 (Cohen’s d = 0.541) compared to the placebo group. Additionally, the rosiglitazone group demonstrated significantly higher response rates until weeks 4 (50.0% vs. 24.2%) and 6 (84.4% versus 51.5%). By week 6, the remission rate was nonsignificantly higher in the rosiglitazone group (18.8%) than in the placebo group (9.1%). Side effect frequencies were comparable. In conclusion, rosiglitazone was beneficial for depressive symptoms of patients with MDD safely and tolerably. Further long‐term, large‐scale studies are recommended to confirm this evidence. Trial Registration: ClinicalTrials.gov identifier: IRCT20090117001556N152
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Psychiatric Research Center, Roozbeh Psychiatric Hospital, Tehran University of Medical Sciences, Tehran, Iran, tums.ac.ir.
- Department of Psychiatry, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran, uswr.ac.ir.
ORCID-Profile: Ahmad Shamabadi, Mohamadjavad Ershadmanesh, Shahin Akhondzadeh
Zitieren
APA
Shamabadi, A., Karami, R., Sadati, S., Farahmand, K., Ershadmanesh, M., Moosavi, R., Rahiminejad, F., Khodaei Ardakani, M. R., & Akhondzadeh, S. (2026). Rosiglitazone Adjunct to Sertraline for Major Depressive Disorder: A Randomized, Double‐Blind, Placebo‐Controlled Trial. Depression and Anxiety, 2026(1). https://doi.org/10.1155/da/5812795
Vancouver
Shamabadi A, Karami R, Sadati S, Farahmand K, Ershadmanesh M, Moosavi R, et al. Rosiglitazone Adjunct to Sertraline for Major Depressive Disorder: A Randomized, Double‐Blind, Placebo‐Controlled Trial. Depression and Anxiety. 2026;2026(1). doi:10.1155/da/5812795
BibTeX
@article{Shamabadi2026,
author = {Shamabadi, Ahmad and Karami, Reihane and Sadati, Sherinaz and Farahmand, Kimia and Ershadmanesh, Mohamadjavad and Moosavi, Rozhin and Rahiminejad, Fatemeh and Khodaei Ardakani, Mohammad-Reza and Akhondzadeh, Shahin},
title = {Rosiglitazone Adjunct to Sertraline for Major Depressive Disorder: A Randomized, Double‐Blind, Placebo‐Controlled Trial},
journal = {Depression and Anxiety},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/da/5812795}
}
EUVIMED